Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials

L. Neuen, Brendon; Oshima, Megumi; Agarwal, Rajiv; Arnott, Clare; Z. Cherney, David; Edwards, Robert; Maria Langkilde, Anna; W. Mahaffey, Kenneth; K. McGuire, Darren; Neal, Bruce; Perkovic, Vlado; Pong, Annpey; S. Sabatine, Marc; Raz, Itamar; Toyama, Tadashi; Wanner, Christoph; C. Wheeler, David; D. Wiviott, Stephen; Zinman, Bernard; J.L. Heerspink, Hiddo

doi:10.1161/circulationaha.121.057736

Public

Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials

Published in Circulation • Apr 8, 2022

Authors:

Brendon L. Neuen

Megumi Oshima

Rajiv Agarwal

Abstract

Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor antagonists, which improve clinical outcomes in people with chronic kidney disease or systolic heart failure. Sodium-glucose c...

Subject

Medicine

Hyperkalemia

Type 2 diabetes

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!